公开(公告)号：US20140194350A1

公开(公告)日：2014-07-10

申请号：US14146161

申请日：2014-01-02

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Yat Sun Or ,  Jun Ma ,  Guoqiang Wang ,  Jiang Long ,  Bin Wang

IPC: A61K38/12 ,  C07K5/097

CPC classification number: C07K5/123 ,  A61K38/00 ,  A61K38/12 ,  A61K45/06 ,  C07K5/06034 ,  C07K5/0808 ,  C07K5/0823 ,  C07K5/0827 ,  C07K14/811

Abstract: The present invention discloses compounds of Formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract translation: 本发明公开了式I化合物或其药学上可接受的盐，酯或前药：其抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。 因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。 本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。

公开(公告)号：US20240140922A1

公开(公告)日：2024-05-02

申请号：US18236560

申请日：2023-08-22

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Samuel Bartlett ,  Joseph D. Panarese ,  Sourav Ghorai ,  Nathaniel Thomas Kenton ,  Sean Rafferty ,  Jonathan Thielman ,  Peilin Xu ,  Bin Wang ,  William Cassels ,  Scott Mitchell ,  Yat Sun Or

IPC: C07D285/36 ,  A61P31/20 ,  C07D337/08 ,  C07D417/04 ,  C07D417/08 ,  C07D417/12 ,  C07D417/14 ,  C07D487/04 ,  C07D513/04 ,  C07F9/6536

CPC classification number: C07D285/36 ,  A61P31/20 ,  C07D337/08 ,  C07D417/04 ,  C07D417/08 ,  C07D417/12 ,  C07D417/14 ,  C07D487/04 ,  C07D513/04 ,  C07F9/6536

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, thereof:




which inhibit the cellular entry of hepatitis B virus (HBV) and/or hepatitis D virus (HDV) or interfere with the function of the life cycle of HBV and/or HDV and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV and/or HDV infection. The invention also relates to methods of treating an HBV and/or HDV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：US20230416268A1

公开(公告)日：2023-12-28

申请号：US18139506

申请日：2023-04-26

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Yat Sun Or ,  Joseph D. Panarese ,  Guoqiang Wang ,  Jing He ,  Jiang Long ,  Jun Ma ,  Bin Wang ,  Sourav Ghorai

IPC: C07D495/04

CPC classification number: C07D495/04

Abstract: The present invention provides compounds of Formula (I),




pharmaceutical compositions comprising these compounds and methods of using these compounds for treating a metabolic disease or liver condition. The present invention relates generally to compounds and pharmaceutical compositions useful as 17β-HSD13 inhibitors. Specifically, the present invention relates to compounds useful as inhibitors of 17β-HSD13 and methods for their preparation and use.

公开(公告)号：US11555032B2

公开(公告)日：2023-01-17

申请号：US16871551

申请日：2020-05-11

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Guoqiang Wang ,  Jun Ma ,  Bin Wang ,  Ruichao Shen ,  Xuechao Xing ,  Yong He ,  Yat Sun Or

IPC: C07D417/12 ,  C07D413/12 ,  C07D417/14 ,  C07D261/08 ,  C07D413/14

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated as FXR modulators. Specifically, the present invention relates to isoxazole derivatives useful as agonists for FXR, and methods for their preparation and use.

公开(公告)号：US10689391B2

公开(公告)日：2020-06-23

申请号：US16217749

申请日：2018-12-12

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Yat Sun Or ,  Jun Ma ,  Guoqiang Wang ,  Xuechao Xing ,  Ruichao Shen ,  Bin Wang

IPC: C07D491/048 ,  C07D493/04 ,  C07D487/04 ,  C07D417/14

Abstract: The present invention provides compounds of Formula (I), and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.

公开(公告)号：US10450306B2

公开(公告)日：2019-10-22

申请号：US15724919

申请日：2017-10-04

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Jun Ma ,  Guoqiang Wang ,  Bin Wang ,  Xuechao Xing ,  Ruichao Shen ,  Jing He ,  Yat Sun Or

IPC: C07D261/08 ,  C07D413/12 ,  C07D413/14 ,  C07D417/14

Abstract: The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.

公开(公告)号：US10450301B2

公开(公告)日：2019-10-22

申请号：US15988806

申请日：2018-05-24

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Brett Granger ,  Guoqiang Wang ,  Ruichao Shen ,  Jing He ,  Yong He ,  Xuechao Xing ,  Jun Ma ,  Jiang Long ,  Bin Wang ,  Yat Sun Or

IPC: A61K31/4375 ,  A61K31/4725 ,  C07D401/14 ,  C07D471/04 ,  C07D471/08 ,  C07D417/14 ,  C07D451/02 ,  C07D451/06

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).

公开(公告)号：US20180362501A1

公开(公告)日：2018-12-20

申请号：US15988763

申请日：2018-05-24

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Guoqiang Wang ,  Brett Granger ,  Ruichao Shen ,  Yong He ,  Xuechao Xing ,  Jun Ma ,  Jiang Long ,  Jing He ,  Bin Wang ,  Yat Sun Or

IPC: C07D401/14 ,  C07D491/107 ,  C07D498/08 ,  C07D401/04

CPC classification number: C07D401/14 ,  C07D401/04 ,  C07D491/107 ,  C07D498/08

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, ester, stereoisomer, tautomer, solvate, hydrate, or combination thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).

公开(公告)号：US10138228B2

公开(公告)日：2018-11-27

申请号：US15597423

申请日：2017-05-17

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Yat Sun Or ,  Yong He ,  Ruichao Shen ,  Xuechao Xing ,  Brett Granger ,  Bin Wang ,  Jun Ma ,  Jing He ,  Jiang Long ,  Guoqiang Wang

IPC: A61K31/42 ,  C07D413/12

Abstract: The present invention provides compounds of Formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated as FXR modulators. Specifically, the present invention relates to isoxazole derivatives useful as agonists for FXR, and methods for their preparation and use.

公开(公告)号：US20180327388A1

公开(公告)日：2018-11-15

申请号：US15979128

申请日：2018-05-14

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Guoqiang Wang ,  Ruichao Shen ,  Jiang Long ,  Jun Ma ,  Xuechao Xing ,  Yong He ,  Brett Granger ,  Jing He ,  Bin Wang ,  Yat Sun Or

IPC: C07D401/14 ,  C07D417/14 ,  C07D405/14 ,  C07D403/12 ,  C07D403/14 ,  C07D413/14

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, ester, stereoisomer, tautomer, solvate, hydrate, or combination thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).